Filana Therapeutics, Inc. FLNA
Set alert
At close · Oct 30
After hours · Oct 30, 4:58 PM ET
- YTD
- -68.59%
- 1 year
- -81.04%
- Open
- 0.6585
- Prev close
- 0.658
- Mkt cap
- 30.05M
- Vol
- 215.57K
- Avg vol
- 2.02M
- EPS
- -0.87
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.62
- High
- 0.6585
News
-
4 days ago benzinga.com
Filana Therapeutics Announces A Study Published By Yale Researchers Of New Preclinical Research On Simufilam Examined Simufilam's Impacts In Human Cell Line To Eliminate Tuberous Sclerosis Complex 2 Gene To Model Cellular Changes
Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex
4 days ago globenewswire.com
Filana Therapeutics Announces Publication in Cells of Promising Preclinical Findings for Simufilam in TSC2-Deficient Cells
Findings provide new insight into simufilam's effects on cellular stress responses and mitochondrial function New research demonstrates a 37% reduction in elevated ATF4, consistent with attenuation…
3 weeks ago globenewswire.com
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for the treatment of Tuberous Sclerosis Complex…
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers DataMEDS AI (NASDAQ:MEDS) stock moved upwards by 39.4% to $4.42 during Thursday's pre-market session. The company's market cap stands at $10.1 million. Stablecoin Development (AMEX:SDEV)…
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. Filana Therapeutics (NASDAQ:FLNA)…
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Jaguar Health (NASDAQ:JAGX) shares moved upwards by 32.2% to $45.56 during Tuesday's after-market session. The company's market cap stands at $1.1 million. Bullfrog AI Hldgs (NASDAQ:BFRG)…
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Jaguar Health (NASDAQ:JAGX) stock increased by 304.5% to $10.8 during Tuesday's regular session. The company's market cap stands at $1.1 million. Greenland Mines (NASDAQ:GRML) shares moved…
1 month ago benzinga.com
Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward
The U.S. Food and Drug Administration (FDA) on Tuesday removed a clinical hold on the investigational new drug application for Filana Therapeutics, Inc. (NASDAQ:FLNA).
1 month ago benzinga.com
Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward
The FDA lifted a clinical hold on Filana Therapeutics' IND application, allowing a Phase 2a trial for a TSC-related epilepsy treatment.
-
1 month ago benzinga.com
FDA Lifts Clinical Hold Form Filana Therapeutics' Investigational New Drug Application To Initiate Planned Phase 2a Trial In Participants With Tuberous Sclerosis Complex-Related Epilepsy
Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex
1 month ago globenewswire.com
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organization, has identified clinical trial sites, and is…
2 months ago gurufocus.com
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, Aug. 1
2 months ago prnewswire.com
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be…
-
3 months ago benzinga.com
Filana Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate
Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.23) by 18.18 percent. This is a 80.43 percent increase over losses of…
3 months ago globenewswire.com
Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for…
-
5 months ago benzinga.com
Maxim Group Reinstates Buy on Filana Therapeutics, Announces $5 Price Target
Maxim Group analyst Jason McCarthy reinstates Filana Therapeutics (NASDAQ:FLNA) with a Buy and announces $5 price target.
-
5 months ago benzinga.com
Filana Therapeutics Q1 EPS $(0.21) Beats $(0.23) Estimate
Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.23) by 8.7 percent. This is a 56.25 percent increase over losses of…
5 months ago globenewswire.com
Filana Therapeutics Reports Q1 2026 Financial Results and Business Update
AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for…
6 months ago globenewswire.com
Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII
AUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for…
6 months ago defenseworld.net
Zevra Therapeutics (NASDAQ:ZVRA) versus Cassava Sciences (NASDAQ:FLNA) Head-To-Head Contrast
Zevra Therapeutics (NASDAQ: ZVRA - Get Free Report) and Cassava Sciences (NASDAQ: FLNA - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast…